Morningstar US Small Growth Rating $13.91 0.00 (0.00%) As of 09/22/2026 Add Compare Share Share Ratings Stock AnalysisChartRatings Morningstar US Small Growth Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.MSGR Aggregate RatingHold 2.35Holdings in MSGR have an aggregate rating of Hold based on 263 analyst ratings issued in the past year covering 20 companies (89.3% of the portfolio).MSGR Aggregate Price Target$13.91High Prediction$13.91Average Prediction$13.91Low Prediction$13.91Holdings in MSGR have an aggregate price target of $13.91 and a range of $13.91 to $13.91 covering 20 companies (89.3% of the portfolio).MSGR Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy12 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell2 Strong Sell rating(s) Ratings for Stocks Held by Morningstar US Small Growth Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 20 MSGR Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings8.06%VRTXVertex Pharmaceuticals$523.57+1.4%Moderate Buy$573.83 9.6%233.7852 of 5 starsAnalyst Forecast7.99%SCLXScilex$5.12+0.4%Strong Sell10.3288 of 5 stars7.01%ARCTArcturus Therapeutics$14.06+5.7%Moderate Buy$22.43 59.5%113.6259 of 5 starsNews CoverageAnalyst UpgradeGap Up6.62%ALNYAlnylam Pharmaceuticals$247.60+0.4%Moderate Buy$367.20 48.3%234.2335 of 5 starsAnalyst Forecast6.44%MRNAModerna$186.61+2.5%Hold$76.72 -58.9%241.9884 of 5 starsTrending NewsAnalyst Forecast6.17%BNTXBioNTech$98.430.0%Moderate Buy$126.00 28.0%193.964 of 5 starsInsider Trade5.97%SRPTSarepta Therapeutics$18.45-2.6%Hold$24.07 30.4%193.6274 of 5 stars5.78%PTCTPTC Therapeutics$62.20-0.2%Moderate Buy$99.08 59.3%153.588 of 5 starsAnalyst Forecast4.94%MRVIMaravai LifeSciences$7.43+0.7%Hold$6.83 -8.0%41.2035 of 5 starsPositive News4.29%NTLAIntellia Therapeutics$11.75-4.7%Hold$20.98 78.5%232.895 of 5 stars4.24%IONSIonis Pharmaceuticals$44.26+0.8%Moderate Buy$89.20 101.5%223.1303 of 5 starsAnalyst Forecast3.19%CVACCureVac$4.66Strong Sell1N/A3.19%RNAAvidity Biosciences$8.39+0.7%Hold$63.75 659.8%161.6568 of 5 starsNews Coverage3.18%ARWRArrowhead Pharmaceuticals$65.84-1.7%Moderate Buy$98.31 49.3%142.631 of 5 starsAnalyst Forecast2.95%ABUSArbutus Biopharma$4.86+0.1%Moderate Buy$5.00 3.0%21.6196 of 5 starsPositive News2.59%DYNDyne Therapeutics$16.21-0.1%Moderate Buy$32.17 98.4%163.1864 of 5 stars2.10%SGMOSangamo Therapeutics$0.07Reduce$5.50 7,332.4%41.3261 of 5 stars1.84%STOKStoke Therapeutics$25.59-2.0%Moderate Buy$44.25 73.0%113.1128 of 5 starsNews Coverage1.52%PRQRProQR Therapeutics$1.70-0.3%Moderate Buy$7.50 342.5%83.9981 of 5 starsNews Coverage1.20%PEPGPepGen$2.66-2.4%Moderate Buy$11.50 333.1%72.7618 of 5 starsAnalyst Upgrade This page (NYSEARCA:MSGR) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc. (OTCQB: VDTA) is targeting the layers beneath the AI boom - GPU hardware and financing, man...Trading Wire | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe Pentagon Has 120 Days to Solve This Critical Mineral ProblemChina controls roughly 80% of the world's tungsten supply, and new Pentagon sourcing restrictions take effect ...The Tomorrow Investor | SponsoredArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Morningstar US Small Growth Please log in to your account or sign up in order to add this asset to your watchlist. Share Morningstar US Small Growth With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
